Asociación entre los grupos de riesgo de recaída bioquímica de la European Association Of Urology, y la progresión a una segunda recaída bioquímica en pacientes con cáncer de próstata manejados con prostatectomía radical y posterior radioterapia de salvamento

Vista sencilla de ítem
dc.contributor.advisorVillarreal Trujillo, Nicolás
dc.contributor.advisorCamacho López, Paul Anthony
dc.contributor.apolounabCamacho López, Paul Anthony [paul-anthony-camacho-lópez]spa
dc.contributor.apolounabCamacho López, Paul Anthony [paul-anthony-camacho-lópez]
dc.contributor.authorRueda Quijano, Sandra Milena
dc.contributor.cvlacCamacho López, Paul Anthony [0000323578]spa
dc.contributor.googlescholarCamacho López, Paul Anthony [-es&oi=ao]spa
dc.contributor.linkedinCamacho López, Paul Anthony [paulcamachomdepi]
dc.contributor.orcidCamacho López, Paul Anthony [0000-0002-6233-9582]spa
dc.contributor.researchgateVillareal Trujillo, Nicolás [Nicolas-Villarreal-Trujillo-743303]spa
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.coverage.spatialBucaramanga (Santander, Colombia)spa
dc.coverage.temporal2022spa
dc.date.accessioned2023-01-23T14:51:36Z
dc.date.available2023-01-23T14:51:36Z
dc.date.issued2022
dc.degree.nameEspecialista en Urologíaspa
dc.description.abstractHasta el 30% de los pacientes manejados con prostatectomía radical por un cáncer de próstata localizado presentan una recaída bioquímica de la enfermedad. La radioterapia de salvamento con o sin hormonoterapia busca ofrecer la posibilidad de curar a estos pacientes, sin embargo existe un subgrupo de pacientes que luego de lograr un descenso significativo del PSA, presentan un nuevo aumento implicando una nueva progresión de la enfermedad o segunda recaída bioquímica. Se han realizado diferentes esfuerzos por intentar optimizar el manejo de salvamento con el fin de disminuir el riesgo de una progresión (momento de inicio de la radioterapia de salvamento, extensión de la irradiación, asociación con hormonoterapia), así como de identificar variables que predigan este desenlace (grupos de riesgo, hallazgos histopatológicos, cinética del PSA, entre otros). El objetivo de este estudio fue establecer la asociación entre los grupos de riesgo de recaída bioquímica de la EAU con la progresión a una segunda recaída bioquímica. Estudio observacional de tipo cohorte retrospectiva de pacientes diagnosticados con adenocarcinoma de próstata localizado y manejados con prostatectomía radical en FOSCAL o FOSCAL Internacional desde el 1 de enero de 2010 al 31 diciembre de 2021, con posterior diagnóstico de recaída bioquímica y manejados con radioterapia de salvamento. No logramos identificar variables que se asocien a una segunda recaída bioquímica. La clasificación de riesgo propuesta por la EAU y el uso de hormonoterapia de forma conjunta con la radioterapia de salvamento, no se relacionaron con la progresión a este desenlacespa
dc.description.abstractenglishUp to 30% of patients managed with radical prostatectomy for localized prostate cancer present a biochemical relapse of the disease. Salvage radiotherapy with or without hormone therapy seeks to offer the possibility of curing these patients; however, there is a subgroup of patients who, after achieving a significant decrease in PSA, present a new increase, implying a new progression of the disease or a second biochemical relapse. . Different efforts have been made to try to optimize salvage management in order to reduce the risk of progression (time of initiation of salvage radiotherapy, extension of irradiation, association with hormone therapy), as well as to identify variables that predict this. outcome (risk groups, histopathological findings, PSA kinetics, among others). The aim of this study was to establish the association between risk groups for biochemical relapse of UAE with progression to a second biochemical relapse. Retrospective cohort observational study of patients diagnosed with localized prostate adenocarcinoma and managed with radical prostatectomy at FOSCAL or FOSCAL International from January 1, 2010 to December 31, 2021, with subsequent diagnosis of biochemical relapse and managed with salvage radiotherapy. We were unable to identify variables that are associated with a second biochemical relapse. The risk classification proposed by the EAU and the use of hormone therapy in conjunction with salvage radiotherapy were not related to progression to this outcome.spa
dc.description.degreelevelEspecializaciónspa
dc.description.learningmodalityModalidad Presencialspa
dc.description.tableofcontents1. LISTA DE TABLAS 2. LISTA DE FIGURAS 3. LISTA DE ANEXOS 4. GLOSARIO 5. RESUMEN 5.1.ESPAÑOL 5.2. INGLÉS 6. DESCRIPCIÓN DEL PROYECTO 6.1.PLANTEAMIENTO DEL PROBLEMA DE INVESTIGACIÓN Y SU JUSTIFICACIÓN EN TÉRMINOS DE NECESIDADES Y PERTINENCIA 7. MARCO TEÓRICO Y ESTADO DEL ARTE 8. OBJETIVOS 8.1.1. GENERAL 8.1.2. ESPECÍFICOS 9. METODOLOGÍA 9.1.1. TIPO DE ESTUDIO 9.1.2. POBLACIÓN A ESTUDIO 9.1.3. TAMAÑO DE LA MUESTRA 9.1.4. CRITERIOS DE INCLUSIÓN 9.1.5. CRITERIOS DE EXCLUSIÓN 9.1.6. VARIABLES 9.1.7. PROCEDIMIENTO 9.1.8. CONTROL DE CALIDAD 9.1.8.1. PROCESAMIENTO Y CONTROL DE LA CALIDAD DE LOS DATOS 9.1.8.2. MONITOREO DE LOS DATOS Y PLAN DE ANÁLISIS 9.1.8.3. ANÁLISIS DE LOS DATOS 10.DISPOSICIONES VIGENTES 10.1. IMPACTO AMBIENTAL 10.2. CONSIDERACIONES ÉTICAS 11. RESULTADOS 12.DISCUSIÓN 13.CONCLUSIONES 14.REFERENCIAS BIBLIOGRÁFICAS 15.TABLAS 16.FIGURAS 17.ANEXOSspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.identifier.urihttp://hdl.handle.net/20.500.12749/18767
dc.language.isospaspa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.publisher.programEspecialización en Urologíaspa
dc.relation.references[1] Humphrey PA. Cancers of the male reproductive organs. In: World Cancer Report, Stewart BW, Wild CP (Eds), World Health Organization, Lyon 2014.spa
dc.relation.references[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68:394-424.spa
dc.relation.references[3] Globocan 2020. Cancer Today. Colombia. https://gco.iarc.fr/today/online-analysis-table?v=2018&mode=cancer&mode_p opulation=continents&population=900&populations=170&key=asr&sex=1&ca ncer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_grou p%5B%5D=0&ages_group%5B%5D=17&nb_items=5&group_cancer=1&inclu de_nmsc=1&include_nmsc_other=1#collapse-group-0-1spa
dc.relation.references[4] Pompe RS, Gild P, Karakiewicz PI, et al. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. Prostate 2018;78:676–81.spa
dc.relation.references[5] Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–7.spa
dc.relation.references[6] Tilki D, Preisser F, Graefen M, Huland H, Pompe RS. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. Eur Urol. 2019;75:896-900.spa
dc.relation.references[7] Stamey TA, Kabalin JN, McNeal JE, Jhonstone IM, Freiha F, Redwine EA, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989;141:1076.spa
dc.relation.references[8] Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol.2001;165:1156-51.spa
dc.relation.references[9] Toussi A, Stewart-Merrill SB, Boorjia SA, Psutka SP, Thompson RH, Frank I, et al. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? J Urol. 2016;195:1754-9.spa
dc.relation.references[10] Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco Jr FJ, Lilja H et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973-8.spa
dc.relation.references[11] Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S, et al. Prostate Cancer. European Association of Urology. http://uroweb.org/individual-guidelines/oncology-guidelines/spa
dc.relation.references[12] Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75:967-87.spa
dc.relation.references[13] Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Berhstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59:893-9.spa
dc.relation.references[14] Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–9.spa
dc.relation.references[15] Boorjian SA, Karness RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009;182:2708-14.spa
dc.relation.references[16] ICECap Working Group. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015;107:djv261.spa
dc.relation.references[17] Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al . Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017;35:3097-104.spa
dc.relation.references[18] Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, et al. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016;34:3864-71.spa
dc.relation.references[19] Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65:1034-43.spa
dc.relation.references[20] Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, et al. Salvage radiotherapy after prostatectomy - what is the best time to treat? Radiother Oncol. 2012;103:239-43.spa
dc.relation.references[21] Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modeling. Eur J Cancer. 2012;48:837-44.spa
dc.relation.references[22] Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Int J Radiat Oncol Biol Phys. 2009;73:1009-16.spa
dc.relation.references[23] Stephenson AJ, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein E a, et al. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. 2012;291(11):1325–32.spa
dc.relation.references[24] Miyake M, Tanaka N, Asakawa I, Morizawa Y, Anai S, Torimoto K, et al. Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study. Radiat Oncol. 2014;9:208spa
dc.relation.references[25] Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017;376:417-28.spa
dc.relation.references[26] Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17:747-56.spa
dc.relation.references[27] Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910-4.spa
dc.relation.references[28] Kane CJ, Im R, Amling CL, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010;76:695-700.spa
dc.relation.references[29] Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171:1393-401.spa
dc.relation.references30] Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035-41.spa
dc.relation.references[31] Mantilla-Rey DJ, Villareal-Trujillo N, Camacho-López PA. Relación entre el valor del antígeno prostático específico al momento de iniciar radioterapia de salvamento posterior a prostatectomía radical y la progresión a recaída bioquímica en pacientes con cáncer de próstata. Trabajo de tesis para optar por el título de especialista en Urología de la Universidad Autónoma de Bucaramanga. 2019.spa
dc.relation.uriapolohttps://apolo.unab.edu.co/en/persons/paul-anthony-camacho-l%C3%B3pezspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.localAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subject.keywordsMedical sciencesspa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsUrologyspa
dc.subject.keywordsMedicinespa
dc.subject.keywordsRadiotherapyspa
dc.subject.keywordsCancerspa
dc.subject.keywordsCancer (Treatment)spa
dc.subject.keywordsProstate neoplasmsspa
dc.subject.keywordsCancer (Reoperation)spa
dc.subject.lembUrologíaspa
dc.subject.lembMedicinaspa
dc.subject.lembCiencias médicasspa
dc.subject.lembCáncer (Tratamiento)spa
dc.subject.lembNeoplasmas de la próstataspa
dc.subject.lembCáncer (Reintervención quirúrgica)spa
dc.subject.proposalCiencias de la saludspa
dc.subject.proposalRadioterapiaspa
dc.subject.proposalCáncerspa
dc.titleAsociación entre los grupos de riesgo de recaída bioquímica de la European Association Of Urology, y la progresión a una segunda recaída bioquímica en pacientes con cáncer de próstata manejados con prostatectomía radical y posterior radioterapia de salvamentospa
dc.title.translatedAssociation between the risk groups for biochemical relapse of the European Association of Urology, and progression to a second biochemical relapse in patients with prostate cancer managed with radical prostatectomy and subsequent salvage radiotherapyspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM

Archivos

Bloque original

Mostrando 1 - 3 de 3
Miniatura
Nombre:
2022_Tesis_Rueda_Quijano_Sandra_Milena.pdf
Tamaño:
448.2 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis
Descargar
Miniatura
Nombre:
2022_Presentación_Rueda_Quijano_Sandra_Milena.pdf
Tamaño:
2.27 MB
Formato:
Adobe Portable Document Format
Descripción:
Presentación
Descargar
Miniatura
Nombre:
2022_Licencia_Rueda_Quijano_Sandra_Milena.pdf
Tamaño:
60.79 KB
Formato:
Adobe Portable Document Format
Descripción:
Licencia
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
829 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización en Urología